© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Apr 29, 2016, the consensus forecast amongst 28 polled investment analysts covering GlaxoSmithKline plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 21, 2013. The previous consensus forecast advised that GlaxoSmithKline plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 23 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,500, with a high estimate of 1,865 and a low estimate of 1,272. The median estimate represents a 2.81% increase from the last price of 1,459. View Full Financials
In 2015, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, equaling last years dividend. The 24 analysts covering the company expect dividends of 0.82 GBP for the upcoming fiscal year, an increase of 2.13%. View Full Financials
|Div growth (TTM)||0.00%|
On Apr 27, 2016, GlaxoSmithKline plc reported 1st quarter 2016 earnings of 0.198 per share. This result exceeded the 0.18 consensus of the 13 analysts covering the company and exceeded last year's 1st quarter results by 14.45%.
The next earnings announcement is expected on Jul 27, 2016. View Full Interim Financials
|Average growth rate||+5.26 %|
GlaxoSmithKline plc reported annual 2015 earnings of 0.757 per share on Feb 03, 2016. View Full Annual Financials
|Average growth rate||-9.56 %|
GlaxoSmithKline plc had 1st quarter 2016 revenues of 6.23bn. This bettered the 6.01bn consensus of the 13 analysts covering the company. This was 10.80% above the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+2.62 %|
GlaxoSmithKline plc had revenues for the full year 2015 of 23.92bn. This was 3.99% above the prior year's results. View Full Annual Financials
|Average growth rate||-3.11 %|